Last $42.92 USD
Change Today +0.73 / 1.73%
Volume 1.2M
XON On Other Exchanges
As of 8:04 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/23/15 - $45.10
52 Week Low
05/9/14 - $13.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and database systems for mapping cellular pathways, as well as its computational modeling and simulation platform; LEAP, a proprietary laser-enabled analysis and processing technology; and mAbLogix, a proprietary antibody discovery platform that enables production of B-cell libraries for discovery of antibodies. It has collaborations with ZIOPHARM Oncology, Inc.; Elanco, Inc.; Fibrocell Science, Inc.; Oragenics, Inc.; Synthetic Biologics, Inc.; AquaBounty Technologies, Inc.; AmpliPhi BioSciences Corp.; Genopaver, LLC; and Soligenix, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in West Palm Beach, Florida.

223 Employees
Last Reported Date: 03/31/14
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals S...
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

Intrexon Corporation and ZIOPHARM Oncology Announce Licensing Agreement with The University of Texas MD Anderson Cancer Center

Intrexon Corporation and ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon’s technology suite and ZIOPHARM’s clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy. Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.

Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM

Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Randal J. Kirk, Chairman, Chief Executive Officer and President.

Intrexon Corporation Appoints Peter Emtage as Vice President, Synthetic Immunology

Intrexon Corporation announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology. Dr. Emtage will focus on further advancing the company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies. Dr. Emtage brings to Intrexon over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Most recently, Dr. Emtage was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $42.92 USD +0.73

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $183.11 USD -1.79
MorphoSys AG €73.61 EUR -0.89
XOMA Corp $3.83 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 87.8x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at